Invios GmbH

https://www.invios.com

LinkedIn: https://www.linkedin.com/company/invios-innovative-immuno-oncology

	Start	2021-12-21 established (s-off)
	Predecessor	Apeiron Biologics AG
	Industry	cancer immunotherapy (immuno-oncology, I-O)
	Industry 2	cell therapy
	Person	Llewellyn-Davies, Peter (Apeiron 201807– CEO before CFO+CBO before Accellerate Partners + Medigene + Wilex)

	Region	Wien (Vienna)
	Country	Austria
	Street	5 Campus-Vienna-Biocenter
	City	1030 Wien
	Tel	+43-1-86565-77
		Address record changed: 2024-01-05

Basic data	Employees	n. a.


		Record changed: 2023-09-11

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Invios GmbH

[1] Invios GmbH. (9/5/23). "Press Release: Invios Starts Further Clinical Trial of APN401, Novel Cell Therapy Against Solid Cancers, and Secures Major Austrian Grant Funding". Vienna....
[2] Apeiron Biologics AG. (4/26/22). "Press Release: Apeiron Shareholders Approve New Group Structure Geared towards Enabling Innovation and Growth". Vienna....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)